LungLife AI (LSE:LLAI) FCF Margin % : -10,500.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is LungLife AI FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. LungLife AI's Free Cash Flow for the six months ended in Dec. 2023 was £-1.89 Mil. LungLife AI's Revenue for the six months ended in Dec. 2023 was £0.02 Mil. Therefore, LungLife AI's FCF Margin % for the quarter that ended in Dec. 2023 was -10,500.00%.

As of today, LungLife AI's current FCF Yield % is -69.22%.

The historical rank and industry rank for LungLife AI's FCF Margin % or its related term are showing as below:

LSE:LLAI' s FCF Margin % Range Over the Past 10 Years
Min: -24345 Med: -3653.43 Max: -218.17
Current: -11200

During the past 6 years, the highest FCF Margin % of LungLife AI was -218.17%. The lowest was -24345.00%. And the median was -3653.43%.

LSE:LLAI's FCF Margin % is ranked worse than
99.55% of 222 companies
in the Medical Diagnostics & Research industry
Industry Median: -12.255 vs LSE:LLAI: -11200.00

LungLife AI FCF Margin % Historical Data

The historical data trend for LungLife AI's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LungLife AI FCF Margin % Chart

LungLife AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-2,504.81

-1,400.00

-4,802.04

-24,345.00

-11,186.11

LungLife AI Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial					-6,800.00	-33,975.00	-19,272.73	-11,900.00	-10,500.00

Competitive Comparison of LungLife AI's FCF Margin %

For the Diagnostics & Research subindustry, LungLife AI's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LungLife AI's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, LungLife AI's FCF Margin % distribution charts can be found below:

* The bar in red indicates where LungLife AI's FCF Margin % falls into.

LungLife AI FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

LungLife AI's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-4.027	/	0.036
	=	-11,186.11 %

LungLife AI's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.89	/	0.018
	=	-10,500.00 %

LungLife AI FCF Margin % Related Terms

Thank you for viewing the detailed overview of LungLife AI's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

LungLife AI (LSE:LLAI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LungLife AI Inc (LSE:LLAI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2545 W. Hillcrest Drive, Suite 140, Thousand Oaks, CA, USA, 91320

Website

https://www.lunglifeai.com

LungLife AI Inc is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence. Its LungLB Test is a blood-based tool developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer.

LungLife AI (LSE:LLAI) Headlines

No Headlines